A5035374413- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Lipoproteins and Cardiovascular Health
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Infective Endocarditis Diagnosis and Management
- Peripheral Artery Disease Management
- Cardiac Imaging and Diagnostics
- Antimicrobial Resistance in Staphylococcus
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Valve Diseases and Treatments
- Coronary Artery Anomalies
- Vitamin K Research Studies
- Cardiac tumors and thrombi
- Cardiac Health and Mental Health
- Education, Psychology, and Social Research
- Blood Pressure and Hypertension Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Streptococcal Infections and Treatments
- Congenital Heart Disease Studies
- Health Systems, Economic Evaluations, Quality of Life
Krajská nemocnice T. Bati
2010-2024
Centre Hospitalier Universitaire de Liège
2022
University of Liège
2019-2022
Maria Cecilia Hospital
2022
Shaheed Rajaei Cardiovascular Medical and Research Center
2022
Institute of Clinical and Experimental Medicine
2019
Associazione Nazionale Medici Cardiologi Ospedalieri
2019
Dnipropetrovsk State Medical Academy
2006
Maastricht University Medical Centre
2006
Baťa (Czechia)
2006
Despite common European Society of Cardiology recommendations, adherence to guideline therapy varies, both temporally and geographically. We sought examine current differences in the use guideline-recommended therapies among 14 countries patients with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). Data were obtained from Antiplatelet Therapy Observational Registry (APTOR), a non-interventional, prospective observational cohort study enrolling ACS PCI. Medication...
Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardial infarction (AMI). CS can affect the pharmacokinetics pharmacodynamics medications. The unique properties cangrelor make it optimal P2Y12 inhibitor for CS-AMI, in terms both efficacy safety. DAPT-SHOCK-AMI trial (ClinicalTrials.gov: NCT03551964; EudraCT: 2018-002161-19) will assess benefits patients with an initial CS-AMI undergoing primary angioplasty. This randomised, multicentre, placebo-controlled...
Thrombotic events are reduced with cangrelor, an intravenous P2Y
Abstract Background The COMBO drug eluting stent is a novel device with luminal endothelial progenitor cell capture technology for rapid homogeneous endothelialization. Methods and results We examined sex differences in 1‐year outcomes after stenting from the collaboration, pooled patient‐level dataset MASCOT REMEDEE multicenter registries. primary endpoint was target lesion failure (TLF), composite of cardiac death, vessel‐myocardial infarction (TV‐MI), or clinically driven...
Dušnost je jedním z hlavních příznaků pacientů s chronickým srdečním selháním. V poslední době narůstá povědomí o tom, že postupnou progresí chronického onemocnění paliativní symptomatická léčba důležitou součástí komplexního přístupu. Právě opioidy se zdají být vhodnými léky k symptomatické léčbě refrakterní dušnosti u pokročilým Randomizované kontrolované studie prokázaly, podávání systémových opioidů vede jednoznačně ke zmírnění dušnosti. Popsané mechanismy účinku zahrnují snížení...
While there have been a number of studies reporting the incidence and implications elevated troponin levels after percutaneous coronary intervention (PCI), body information about incidence, associations, following angiography (CAG) is limited.A total 220 consecutive patients with stable artery disease or intermediate low-risk acute syndrome without persistent ST-segment elevation (NSTE-ACS) were included in our study. High-sensitivity cardiac I (hs-cTnI) measured before PCI correlated...
Vrozené anomálie koronárních tepen jsou v populaci vzácné.Existuje několik variant této anomálie, avšak jako maligní varianta je popisována ta, při které levá věnčitá tepna odstupuje z pravého koronárního sinu a prochází mezi aortou truncus pulmonalis.Pokud se u pacienta tato manifestuje náhlou srdeční smrtí pacient přežije, doporučena chirurgická korekce vady.Ke zvážení je, zda pacientovi následně implantovat kardioverter
The COMBO stent is a biodegradable-polymer sirolimus-eluting with endothelial progenitor cell capture technology for faster endothelialization. We analyzed outcomes in relation to bleeding risk using the PARIS score. MASCOT was an international registry of all-comers undergoing attempted implantation. stratified patients as low bleeding-risk (LBR) score ≤ 3 and intermediate-to-high (IHBR) > based on baseline age, body mass index, anemia, current smoking, chronic kidney disease need triple...
Felsoci, M.; Parenica, J.; Jarkovsky, Widimsky, Linhart, A.; Malek, F.; Fedorco, Coufal, Z.; Miklik, R.; Spinar, J. Author Information